Journal
SCHIZOPHRENIA RESEARCH
Volume 88, Issue 1-3, Pages 222-226Publisher
ELSEVIER
DOI: 10.1016/j.schres.2006.07.025
Keywords
schizophrenia; antipsychotic medication; weight gain; quality of life
Categories
Ask authors/readers for more resources
Background: Metabolic abnormalities and weight gain are an important problem in patients with schizophrenia. An instrument to evaluate body image and self-esteem related to weight has recently been developed (B-WISE (R)). The first objective was to evaluate whether the findings of the original validation study could be confirmed in a European sample. The second objective was to explore the association of B-WISE (R) scores with the metabolic syndrome and glucose abnormalities. Methods: A Dutch translation of B-WISE (R) was tested in a large sample of patients with schizophrenia (n=300) who underwent an extensive metabolic screening. Results: The original findings with B-WISE (R) were confirmed in an independent sample. Scores on B-WISE (R) differed significantly as a function of BMI. Scores on B-WISE (R) also differentiated patients with and without the metabolic syndrome and glucose abnormalities. Patients experiencing a recent weight gain had lower self-esteem and poorer psychosocial adaptation. Conclusion: B-WISE (R) could be a useful instrument to evaluate the subjective psychosocial consequences associated with current weight and weight gain in patients with schizophrenia. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available